Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi

Transfusion

Volumn 50, Issue 10, 2010, Pages 2220-2232

  Agapova, Maria ^a,b,c   Busch, Michael P ^a,b,c   Custer, Brian ^a,b,c  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APHERESIS; ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; HUMAN; QUALITY ADJUSTED LIFE YEAR; RECIPIENT; SCREENING TEST; SENSITIVITY ANALYSIS; SEROPREVALENCE; SURVIVAL RATE; TRYPANOSOMA CRUZI;

ANIMALS; BLOOD DONORS; BLOOD TRANSFUSION; CHAGAS DISEASE; COST-BENEFIT ANALYSIS; HUMANS; MASS SCREENING; TRYPANOSOMA CRUZI; UNITED STATES;

EID: 78649484203     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02686.x     Document Type: Article

References (40)

1. Raether W, Michel R, Uphoff M. Effects of dimethylsulfoxide and the deep-freezing process on the infectivity, motility, and ultrastructure of Trypanosoma cruzi. Parasitol Res 1988;74:307-13.
2. Kirchhoff LV, Paredes P, Lomeli-Guerrero A, Paredes- Espinoza M, Ron-Guerrero CS, Delgado-Mejía M, Peña- Muñoz JG. Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 2006;46:298-304.
3. Ferreira MS, Borges AS. Some aspects of protozoan infections in immunocompromised patients-a review. Mem Inst Oswaldo Cruz 2002;97:443-57.
4. Da-Cruz AM, Igreja RP, Dantas W, Junqueira AC, Pacheco RS, Silva-Gonçalves AJ, Pirmez C. Long-term follow-up of co-infected HIV and Trypanosoma cruzi Brazilian patients. Trans R Soc Trop Med Hyg 2004;98:728-33.
5. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin- Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007;298:2171-81.
6. Piron M, Verges M, Munoz J, Casamitjana N, Sanz S, Maymó RM, Hernández JM, Puig L, Portús M, Gascón J, Sauleda S. Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion 2008;48:1862-8.
7. El Ghouzzi MH, Boiret E, Wind F, Brochard C, Fittere S, Paris L, Mazier D, Sansonetti N, Bierling P. Testing blood donors for Chagas disease in the Paris area, France: first results after 18 months of screening. Transfusion 2009;50: 575-83.
8. Tobler LH, Contestable P, Pitina L, Groth H, Shaffer S, Blackburn GR, Warren H, Lee SR, Busch MP. Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors. Transfusion 2007; 47:90-6.
9. Staropoli A. Future strategies for U.S. Chagas screening: how new evidence could help shape policy. AABB News 2009; June 13.
10. Stramer L, Townsend L, Foster A, Krysztof E, Noedel P, Caglioti G, Nguyen L, Proctor C, Leiby A. US blood donor screening for Trypanosoma cruzi: clinical studies and first year experience XXX international congress of the ISBT. Macao, SAR, China. Vox Sang 2008;95:296.
11. Kirchhoff LV. Parasitic diseases of the liver and intestines. Gastroenterol Clin 1996;25:518-33.
12. FDA. Blood products advisory committee meeting. Silver Spring (MD): FDA; 2009.
13. Custer B, Busch MP, Marfin AA, Petersen LR. The costeffectiveness of screening the U.S. blood supply forWest Nile virus. Ann Intern Med 2005;143:486-92.
14. Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL. Chagas disease and the US blood supply. Curr Opin Infect Dis 2008;21:476-82.
15. Kamper-Jorgensen M, Ahlgren M, Rostgaard K, Melbye M, Edgren G, Nyrén O, Reilly M, Norda R, Titlestad K, Tynell E, Hjalgrim H. Survival after blood transfusion. Transfusion 2008;48:2577-84.
16. Coura J.R. Chagas disease: what is known and what is needed-a background article. Mem Inst Oswaldo Cruz 2007;102 Suppl 1:113-22.
17. Consumer price index bureau of labor statistics. Department of Labor; 2007.
18. HCUP. Cost-to-Charge Ratio Files (CCR): agency for healthcare research and quality. Rockville (MD): HCUP; 2006.
19. Brouwer WB, Koopmanschap M.A. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics 2005;23:105-11.
20. DeNavas-Walt C, Proctor BD, Smith JC. Income, poverty and health insurance coverage in the United States: 2007. Washington, DC: US Census Bureau; 2008.
21. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11:159-68.
22. Wilson LS, Ramsey JM, Koplowicz YB, Valiente-Banuet L, Motter C, Bertozzi SM, Tobler LH. Cost-effectiveness of implementation methods for ELISA serology testing of Trypanosoma cruzi in California blood banks. Am J Trop Med Hyg 2008;79:53-68.
23. Llewelyn C, Amin M, Malfroy M, Williamson L. Distribution of blood component recipients according to immune status. Presented at Eurosat on 19 October 2004. Transfusion Clinque et Biologique. Accessed at http://www.ints.fr/ pdf/sat04-09-llewelyn.pdf on 15 March 2005.
24. Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009;23:1-12.
25. Hillyer CD, Blumberg N, Glynn SA, Ness PM. Transfusion recipient epidemiology and outcomes research: possibilities for the future. Transfusion 2008;48:1530-7.
26. Castillo-Riquelme M, Chalabi Z, Lord J, Guhl F, Campbell- Lendrum D, Davies C, Fox-Rushby J. Modelling geographic variation in the cost-effectiveness of control policies for infectious vector diseases: the example of Chagas disease. J Health Econ 2008;27:405-26.
27. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353:1471-80.
28. Gerson LB, Triadafilopoulos G, Gage BF. The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. Am J Med 2004; 116:451-9.
29. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102.
30. Agha Z, Lofgren RP, VanRuiswyk JV. Is antibiotic prophylaxis for bacterial endocarditis cost-effective? Med Decis Making 2005;25:308-20.
31. Silva Sde A, Gontijo ED, Amaral CF. Case-control study of factors associated with chronic Chagas heart disease in patients over 50 years of age. Mem Inst Oswaldo Cruz 2007;102:845-51.
32. Teixeira AR, Nitz N, Guimaro MC, Gomes C, Santos-Buch CA. Chagas disease. Postgrad Med J 2006;82:788-98.
33. Bestetti RB, Theodoropoulos TA, Cardinalli-Neto A, Cury PM. Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy. Am Heart J 2008;156:422-30.
34. de Menezes M, Rocha A, da Silva AC, da Silva AM. [Basic causes of death in elderly patients with Chagas' disease]. Arq Bras Cardiol 1989;52:75-8.
35. Rassi A, Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 2007;115:1101-8.
36. Theodoropoulos TA, Bestetti RB, Otaviano AP, Cordeiro JA, Rodrigues VC, Silva AC. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. Int J Cardiol 2008;128:22-9.
37. HCUP. Arkansas State Inpatient Database (SID): agency for healthcare research and quality. Rockville (MD): HCUP; 2007.
38. HCUP. National and regional estimates on hospital use for all patient from the HCUP nationwide inpatient sample: principal procedure and principal diagnosis. Rockville (MD): HCUP; 2006.
39. Gohler A, Conrads-Frank A, Worrell SS, Geisler BP, Halpern EF, Dietz R, Anker SD, Gazelle GS, Siebert U. Decisionanalytic evaluation of the clinical effectiveness and costeffectiveness of management programmes in chronic heart failure. Eur J Heart Fail 2008;10:1026-32.
40. Surgeons ASoCaR. Laparoscopic colectomy is cost-effective for managing sigmoid diverticular disease. In: Guide Ds, editor. DGNews: Peer Review Media. 2002.